Title: Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
Journal: Cancer chemotherapy and pharmacology20110301
Title: Plasma disposition of capecitabine (CCB) and its metabolites 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouracil (5'-DFUR) with two different capecitabine/oxaliplatin dosage regimens.
Journal: International journal of clinical pharmacology and therapeutics20100701
Title: A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Journal: Biomedical chromatography : BMC20100401
Title: Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells.
Journal: Biochemical pharmacology20080201
Title: Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Journal: European journal of cancer (Oxford, England : 1990)20080101
Title: A glucuronidation pathway of capecitabine occurs in rats but not in mice and humans.
Journal: Drug metabolism letters20070401
Title: Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography.
Journal: Journal of chromatography. A20070105
Title: Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20051105
Title: Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide.
Journal: The Journal of pharmacology and experimental therapeutics20050601
Title: Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells.
Journal: BMC cancer20050101
Title: Identification of the cytosolic carboxylesterase catalyzing the 5'-deoxy-5-fluorocytidine formation from capecitabine in human liver.
Journal: Drug metabolism and disposition: the biological fate of chemicals20041001
Title: Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5'-deoxy-5-fluorocytidine formation.
Journal: Drug metabolism and disposition: the biological fate of chemicals20040701
Title: In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
Journal: Cancer research20031115
Title: Isolation of an unknown metabolite of capecitabine, an oral 5-fluorouracil prodrug, and its identification by nuclear magnetic resonance and liquid chromatography-tandem mass spectrometry as a glucuroconjugate of 5'-deoxy-5-fluorocytidine, namely 2'-(beta-D-glucuronic acid)-5'-deoxy-5-fluorocytidine.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20030725
Title: Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
Journal: Bioorganic & medicinal chemistry letters20030310
Title: Forced expression of cytidine deaminase confers sensitivity to capecitabine.
Journal: Oncology20030101
Title: Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
Journal: International journal of clinical pharmacology and therapeutics20021201
